PL2373631T3 - Związki przeciwbakteryjne - Google Patents

Związki przeciwbakteryjne

Info

Publication number
PL2373631T3
PL2373631T3 PL09795514T PL09795514T PL2373631T3 PL 2373631 T3 PL2373631 T3 PL 2373631T3 PL 09795514 T PL09795514 T PL 09795514T PL 09795514 T PL09795514 T PL 09795514T PL 2373631 T3 PL2373631 T3 PL 2373631T3
Authority
PL
Poland
Prior art keywords
antibacterial compounds
antibacterial
compounds
Prior art date
Application number
PL09795514T
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of PL2373631T3 publication Critical patent/PL2373631T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
PL09795514T 2008-12-02 2009-12-01 Związki przeciwbakteryjne PL2373631T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
EP09795514.0A EP2373631B1 (en) 2008-12-02 2009-12-01 Antibacterial compounds
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (1)

Publication Number Publication Date
PL2373631T3 true PL2373631T3 (pl) 2015-10-30

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09795514T PL2373631T3 (pl) 2008-12-02 2009-12-01 Związki przeciwbakteryjne
PL14197877.5T PL2907813T3 (pl) 2008-12-02 2009-12-01 Przeciwbakteryjne kompozycje farmaceutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14197877.5T PL2907813T3 (pl) 2008-12-02 2009-12-01 Przeciwbakteryjne kompozycje farmaceutyczne

Country Status (28)

Country Link
US (3) US8975416B2 (pl)
EP (3) EP2373631B1 (pl)
JP (3) JP5665756B2 (pl)
KR (1) KR101643435B1 (pl)
CN (1) CN102227411B (pl)
AU (1) AU2009323854B2 (pl)
BR (2) BRPI0922220B8 (pl)
CA (1) CA2744962C (pl)
CY (2) CY1116383T1 (pl)
DK (2) DK2373631T3 (pl)
ES (2) ES2537059T3 (pl)
GB (1) GB0821913D0 (pl)
HK (2) HK1162169A1 (pl)
HR (2) HRP20150518T1 (pl)
HU (1) HUE029151T2 (pl)
IL (1) IL213325A (pl)
LT (1) LT2907813T (pl)
MX (1) MX2011005837A (pl)
NZ (1) NZ593111A (pl)
PL (2) PL2373631T3 (pl)
PT (2) PT2907813T (pl)
RS (1) RS54904B1 (pl)
RU (1) RU2525915C2 (pl)
SG (1) SG171939A1 (pl)
SI (2) SI2907813T1 (pl)
SM (2) SMT201500117B (pl)
WO (1) WO2010063996A2 (pl)
ZA (1) ZA201103751B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
ES2803556T3 (es) * 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN105451561A (zh) 2013-02-04 2016-03-30 赛里斯治疗公司 组合物和方法
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
CA3146788A1 (en) * 2019-07-17 2021-01-21 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
PE20240768A1 (es) * 2021-05-24 2024-04-17 Aimmax Therapeutics Inc Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
EP4334298A1 (en) 2021-06-14 2024-03-13 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (pl) * 1974-04-30 1975-11-11
JPS50154250A (pl) * 1974-05-31 1975-12-12
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
AU3696495A (en) * 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
ES2232683T3 (es) 2000-11-27 2005-06-01 Ciba Specialty Chemicals Holding Inc. Derivados de 2-(2-hiddroxifenil)-2h-benzotriazoles, sustituidos en posicion 5 por arilo y en posicion 5 por heteroarilo, como absorbentes uv.
ATE375983T1 (de) 2000-12-15 2007-11-15 Vertex Pharma Bakterielle gyrase-hemmer und deren verwendung
FR2819180B1 (fr) * 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003035065A1 (en) 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
ES2277088T3 (es) 2002-06-13 2007-07-01 Vertex Pharmaceuticals Incorporated Derivados del acido 2-ureido-6-heteroaril-3h-benzoimidazol-4-carboxilico y compuestos relacionados como inhibidores de girasa y/o topoisomerasa iv para el tratamiento de infecciones bacterianas.
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
RU2417996C2 (ru) 2004-11-04 2011-05-10 Вертекс Фармасьютикалз Инкорпорейтед ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
US20090069384A1 (en) 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
EP1945209B1 (en) 2005-08-12 2018-05-30 United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
EP2280705B1 (en) 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
PT2414369E (pt) 2009-04-02 2015-10-22 Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii Derivados de imidazo[2,1-b][1,3,4]tiadiazol
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8377945B2 (en) 2009-06-15 2013-02-19 Rigel Pharmaceuticals Inc. Small molecule inhibitors of spleen tyrosine kinase (SYK)
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile

Also Published As

Publication number Publication date
SMT201600259B (it) 2016-08-31
SI2907813T1 (sl) 2016-09-30
IL213325A (en) 2016-02-29
CN102227411A (zh) 2011-10-26
IL213325A0 (en) 2011-07-31
PT2373631E (pt) 2015-06-09
US20150150861A1 (en) 2015-06-04
EP2907813B1 (en) 2016-04-27
US20120020950A1 (en) 2012-01-26
RU2525915C2 (ru) 2014-08-20
CA2744962C (en) 2017-06-06
PT2907813T (pt) 2016-08-05
NZ593111A (en) 2013-05-31
HRP20150518T1 (hr) 2015-07-17
DK2373631T3 (en) 2015-05-26
JP5665756B2 (ja) 2015-02-04
CY1117934T1 (el) 2017-05-17
CA2744962A1 (en) 2010-06-10
AU2009323854A2 (en) 2011-06-30
EP3095783A1 (en) 2016-11-23
CY1116383T1 (el) 2017-02-08
MX2011005837A (es) 2011-11-18
EP2907813A1 (en) 2015-08-19
PL2907813T3 (pl) 2016-09-30
SI2373631T1 (sl) 2015-08-31
CN102227411B (zh) 2015-10-14
HUE029151T2 (hu) 2017-02-28
RS54904B1 (sr) 2016-10-31
SG171939A1 (en) 2011-07-28
ES2575908T3 (es) 2016-07-04
EP2373631A2 (en) 2011-10-12
US8975416B2 (en) 2015-03-10
DK2907813T3 (en) 2016-07-25
WO2010063996A2 (en) 2010-06-10
BRPI0922220B8 (pt) 2021-05-25
BRPI0922220A8 (pt) 2018-04-03
BR122020013025B1 (pt) 2021-05-18
US9763925B2 (en) 2017-09-19
JP2017048217A (ja) 2017-03-09
AU2009323854B2 (en) 2014-06-26
KR101643435B1 (ko) 2016-07-27
ZA201103751B (en) 2014-10-29
JP2015078220A (ja) 2015-04-23
BRPI0922220B1 (pt) 2021-03-09
AU2009323854A1 (en) 2010-06-10
SMT201500117B (it) 2015-07-09
BRPI0922220A2 (pt) 2015-12-29
US20160184283A1 (en) 2016-06-30
HRP20160597T1 (hr) 2016-09-23
US9314456B2 (en) 2016-04-19
LT2907813T (lt) 2016-10-10
JP2012510458A (ja) 2012-05-10
HK1208668A1 (zh) 2016-03-11
EP2373631B1 (en) 2015-02-25
KR20110093925A (ko) 2011-08-18
HK1162169A1 (en) 2012-08-24
WO2010063996A3 (en) 2010-12-29
RU2011127165A (ru) 2013-01-10
ES2537059T3 (es) 2015-06-02
GB0821913D0 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
HK1162169A1 (en) Antibacterial compounds
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0815484D0 (en) Antibacterial agents
GB0804702D0 (en) Compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
PL2321306T3 (pl) 3-cyjanopirolidynylo-fenylo-oksazolidynony jako środki przeciwbakteryjne
GB0807910D0 (en) Compounds
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0803060D0 (en) Novel antimicrobial compounds
GB0823284D0 (en) Novel antimicrobial compounds
GB0802192D0 (en) Compounds
GB0805498D0 (en) Compounds
GB0801596D0 (en) Compounds
GB0802191D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0802231D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0802587D0 (en) Compounds
GB0803493D0 (en) Compounds
GB0803495D0 (en) Compounds
GB0803496D0 (en) Compounds
GB0804064D0 (en) Compounds